{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:34:15Z","timestamp":1793082855890,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Practice patterns for neovascular age-related macular degeneration (nAMD) have evolved from the landmark registration trials of vascular endothelial growth factor (VEGF) inhibitors. Non-monthly regimens like treat-and-extend (T&amp;E) have become popular due to their effectiveness in clinical practice. T&amp;E regimens attempt to limit the burden of visits and treatments by allowing progressively longer treatment intervals, but in so doing, are potentially associated with the expense of treating quiescent disease. This is acceptable to many patients and their ophthalmologists but can still be problematic in the real-world. Recent studies have further refined the T&amp;E approach by allowing for quicker and longer extension of treatment intervals when less severe disease is detected. With newer drugs offering increased durability, a shift to longer regular intervals may emerge as a new practice pattern for VEGF inhibitor therapy. This review aims to consolidate the current literature on the most effective treatment patterns and update treatment guidelines based on options that are now available. It also summarises new aspects of nAMD management that may help to further refine current practice.<\/jats:p>","DOI":"10.1038\/s41433-024-03370-0","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:04:53Z","timestamp":1728381893000},"page":"860-869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-7081","authenticated-orcid":false,"given":"Kelvin Yi Chong","family":"Teo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Eldem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Joussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Korobelnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-1165","authenticated-orcid":false,"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"L\u00f6vestam-Adrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle A.","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-7058","authenticated-orcid":false,"given":"Lihteh","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-444X","authenticated-orcid":false,"given":"Dinah","family":"Zur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-8143","authenticated-orcid":false,"given":"Javier","family":"Zarranz-Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-4146","authenticated-orcid":false,"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"3370_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"3370_CR2","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","volume":"120","author":"L Kodjikian","year":"2013","unstructured":"Kodjikian L, Souied EH, Mimoun G, Mauget-Fa\u00ffsse M, Behar-Cohen F, Decullier E, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120:2300\u20139.","journal-title":"Ophthalmology"},{"key":"3370_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72\u201384.","journal-title":"Ophthalmology"},{"key":"3370_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","volume":"156","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156:652\u201360.e1.","journal-title":"Am J Ophthalmol"},{"key":"3370_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/jcm11020325","volume":"11","author":"D Veritti","year":"2022","unstructured":"Veritti D, Sarao V, Soppelsa V, Danese C, Chhablani J, Lanzetta P. Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression. J Clin Med. 2022;11:325.","journal-title":"J Clin Med"},{"key":"3370_CR6","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1001\/jamaophthalmol.2019.3305","volume":"137","author":"P Hykin","year":"2019","unstructured":"Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, et al. Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial. JAMA Ophthalmol. 2019;137:1256\u201364.","journal-title":"JAMA Ophthalmol"},{"key":"3370_CR7","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","volume":"97","author":"FG Holz","year":"2013","unstructured":"Holz FG, Bandello F, Gillies M, Mitchell P, Osborne A, Sheidow T, et al. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013;97:1161\u20137.","journal-title":"Br J Ophthalmol"},{"key":"3370_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","volume":"125","author":"P Rao","year":"2018","unstructured":"Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, et al. Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry. Ophthalmology. 2018;125:522\u20138.","journal-title":"Ophthalmology"},{"key":"3370_CR9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A, The Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti\u2013vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259\u201373.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3370_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ajo.2011.09.013","volume":"153","author":"JH Lim","year":"2012","unstructured":"Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012;153:678\u201386.e2.","journal-title":"Am J Ophthalmol"},{"key":"3370_CR11","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.ophtha.2014.04.026","volume":"121","author":"J Zarranz-Ventura","year":"2014","unstructured":"Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The neovascular age-related macular degeneration database: Report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014;121:1966\u201375.","journal-title":"Ophthalmology"},{"key":"3370_CR12","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s00417-018-4100-z","volume":"256","author":"T Bek","year":"2018","unstructured":"Bek T, Klug SE. Incidence and risk factors for neovascular age-related macular degeneration in the fellow eye. Graefes Arch Clin Exp Ophthalmol. 2018;256:2061\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3370_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/aos.15094","volume":"100","author":"M L\u00f6vestam Adrian","year":"2022","unstructured":"L\u00f6vestam Adrian M, Schroeder M, Westborg I. What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register. Acta Ophthalmol. 2022;100:769\u201374.","journal-title":"Acta Ophthalmol"},{"key":"3370_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ophtha.2018.08.023","volume":"126","author":"V Nguyen","year":"2019","unstructured":"Nguyen V, Daien V, Guymer R, Young S, Hunyor A, Fraser-Bell S, et al. Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration. Ophthalmology. 2019;126:64\u201374.","journal-title":"Ophthalmology"},{"key":"3370_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ceo.13038","volume":"46","author":"V Nguyen","year":"2018","unstructured":"Nguyen V, Daien V, Guymer RH, McAllister IL, Morlet N, Barthelmes D, et al. Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular age-related macular degeneration: a prospective study from a long-term observational data set. The Fight Retinal Blindness! Project. Clin Exp Ophthalmol. 2018;46:266\u201374.","journal-title":"Clin Exp Ophthalmol"},{"key":"3370_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.cct.2014.02.003","volume":"37","author":"EY Chew","year":"2014","unstructured":"Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A, et al. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design \u2013 HOME Study report number 1. Contemp Clin Trials. 2014;37:294\u2013300.","journal-title":"Contemp Clin Trials"},{"key":"3370_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/ceo.13097","volume":"46","author":"H Razavi","year":"2018","unstructured":"Razavi H, Baglin E, Sharangan P, Caruso E, Tindill N, Griffin S, et al. Gaming to improve vision: 21st century self-monitoring for patients with age-related macular degeneration. Clin Exp Ophthalmol. 2018;46:480\u20134.","journal-title":"Clin Exp Ophthalmol"},{"key":"3370_CR18","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41433-019-0455-6","volume":"33","author":"MK Schmid","year":"2019","unstructured":"Schmid MK, Thiel MA, Lienhard K, Schlingemann RO, Faes L, Bachmann LM. Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration. Eye. 2019;33:1584\u20139.","journal-title":"Eye"},{"key":"3370_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.oret.2021.02.005","volume":"5","author":"KYC Teo","year":"2021","unstructured":"Teo KYC, Bachmann LM, Sim D, Lee SY, Tan A, Wong TY, et al. Patterns and characteristics of a clinical implementation of a self-monitoring program for retina diseases during the COVID-19 pandemic. Ophthalmol Retina. 2021;5:1245\u201353.","journal-title":"Ophthalmol Retina"},{"key":"3370_CR20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41433-020-0910-4","volume":"35","author":"E Ward","year":"2021","unstructured":"Ward E, Wickens RA, O\u2019Connell A, Culliford LA, Rogers CA, Gidman EA, et al. Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study. Eye. 2021;35:592\u2013600.","journal-title":"Eye"},{"key":"3370_CR21","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.ophtha.2018.02.037","volume":"125","author":"F Grassmann","year":"2018","unstructured":"Grassmann F, Mengelkamp J, Brandl C, Harsch S, Zimmermann ME, Linkohr B, et al. A deep learning algorithm for prediction of age-related eye disease study severity scale for age-related macular degeneration from color fundus photography. Ophthalmology. 2018;125:1410\u201320.","journal-title":"Ophthalmology"},{"key":"3370_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41746-020-00317-z","volume":"3","author":"Y Peng","year":"2020","unstructured":"Peng Y, Keenan TD, Chen Q, Agr\u00f3n E, Allot A, Wong WT, et al. Predicting risk of late age-related macular degeneration using deep learning. NPJ Digit Med. 2020;3:111.","journal-title":"NPJ Digit Med"},{"key":"3370_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1167\/iovs.18-25325","volume":"60","author":"DB Russakoff","year":"2019","unstructured":"Russakoff DB, Lamin A, Oakley JD, Dubis AM, Sivaprasad S. Deep learning for prediction of AMD progression: a pilot study. Invest Ophthalmol Vis Sci. 2019;60:712\u201322.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3370_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s42256-020-0154-9","volume":"2","author":"Q Yan","year":"2020","unstructured":"Yan Q, Weeks DE, Xin H, Swaroop A, Chew EY, Huang H, et al. Deep-learning-based prediction of late age-related macular degeneration progression. Nat Mach Intell. 2020;2:141\u201350.","journal-title":"Nat Mach Intell"},{"key":"3370_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41591-020-0867-7","volume":"26","author":"J Yim","year":"2020","unstructured":"Yim J, Chopra R, Spitz T, Winkens J, Obika A, Kelly C, et al. Predicting conversion to wet age-related macular degeneration using deep learning. Nat Med. 2020;26:892\u20139.","journal-title":"Nat Med"},{"key":"3370_CR26","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","volume":"122","author":"JJ Arnold","year":"2015","unstructured":"Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, et al. Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122:1212\u20139.","journal-title":"Ophthalmology"},{"key":"3370_CR27","first-page":"87","volume":"10","author":"P Hykin","year":"2016","unstructured":"Hykin P, Chakravarthy U, Lotery A, McKibbin M, Napier J, Sivaprasad S, on behalf of the AURA Study Group. A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. Clin Ophthalmol. 2016;10:87\u201396.","journal-title":"Clin Ophthalmol"},{"key":"3370_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ophtha.2014.10.001","volume":"122","author":"MC Gillies","year":"2015","unstructured":"Gillies MC, Campain A, Walton R, Simpson JM, Arnold JJ, Guymer RH, et al. Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab. Ophthalmology. 2015;122:589\u201394.e1.","journal-title":"Ophthalmology"},{"key":"3370_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","volume":"145","author":"CD Regillo","year":"2008","unstructured":"Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239\u201348.e5.","journal-title":"Am J Ophthalmol"},{"key":"3370_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","volume":"118","author":"U Schmidt-Erfurth","year":"2011","unstructured":"Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118:831\u20139.","journal-title":"Ophthalmology"},{"key":"3370_CR31","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00417-020-05048-1","volume":"259","author":"JG Garweg","year":"2021","unstructured":"Garweg JG, Gerhardt C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) \u2013 a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021;259:2181\u201392.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3370_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40123-017-0087-5","volume":"6","author":"M Gemenetzi","year":"2017","unstructured":"Gemenetzi M, Patel PJ. A systematic review of the treat and extend treatment regimen with anti-VEGF agents for neovascular age-related macular degeneration. Ophthalmol Ther. 2017;6:79\u201392.","journal-title":"Ophthalmol Ther"},{"key":"3370_CR33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","volume":"137","author":"MC Gillies","year":"2019","unstructured":"Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, et al. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2019;137:372\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"3370_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-1005-x","volume":"18","author":"P Jaki Mekjavi\u0107","year":"2018","unstructured":"Jaki Mekjavi\u0107 P, Gregor\u010di\u010d B, Ober\u010d C, Podgor\u0161ek S. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia. BMC Ophthalmol. 2018;18:333.","journal-title":"BMC Ophthalmol"},{"key":"3370_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4103\/jovr.jovr_50_18","volume":"13","author":"H Nikkhah","year":"2018","unstructured":"Nikkhah H, Karimi S, Ahmadieh H, Azarmina M, Abrishami M, Ahoor H, et al. Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases: clinical practice guideline. J Ophthalmic Vis Res. 2018;13:158\u201369.","journal-title":"J Ophthalmic Vis Res"},{"key":"3370_CR36","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","volume":"138","author":"PJ Kertes","year":"2020","unstructured":"Kertes PJ, Galic IJ, Greve M, Williams G, Baker J, Lahaie M, et al. Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial. JAMA Ophthalmol. 2020;138:244\u201350.","journal-title":"JAMA Ophthalmol"},{"key":"3370_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mon\u00e9s J, on behalf of the TREND Study Group. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125:57\u201365.","journal-title":"Ophthalmology"},{"key":"3370_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","volume":"1","author":"CC Wykoff","year":"2017","unstructured":"Wykoff CC, Ou WC, Brown DM, Croft DE, Wang R, Payne JF, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retina. 2017;1:314\u201321.","journal-title":"Ophthalmol Retina"},{"key":"3370_CR39","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"U Chakravarthy","year":"2012","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399\u2013411.","journal-title":"Ophthalmology"},{"key":"3370_CR40","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40266-015-0300-y","volume":"32","author":"A Garc\u00eda-Layana","year":"2015","unstructured":"Garc\u00eda-Layana A, Figueroa MS, Araiz J, Ruiz-Moreno JM, G\u00f3mez-Ulla F, Arias-Barquet L, et al. Treatment of exudative age-related macular degeneration: focus on aflibercept. Drugs Aging. 2015;32:797\u2013807.","journal-title":"Drugs Aging"},{"key":"3370_CR41","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying G-S, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908.","journal-title":"N Engl J Med"},{"key":"3370_CR42","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122:2514\u201322.","journal-title":"Ophthalmology"},{"key":"3370_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ajo.2018.05.026","volume":"192","author":"M Okada","year":"2018","unstructured":"Okada M, Kandasamy R, Chong EW, McGuiness M, Guymer RH. The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol. 2018;192:184\u201397.","journal-title":"Am J Ophthalmol"},{"key":"3370_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76354-1","volume":"10","author":"A Ebneter","year":"2020","unstructured":"Ebneter A, Michels S, Pruente C, Imesch P, Eilenberger F, Oesch S, et al. Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration. Sci Rep. 2020;10:20256.","journal-title":"Sci Rep"},{"key":"3370_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajo.2014.09.011","volume":"159","author":"N Rayess","year":"2015","unstructured":"Rayess N, Houston SK III, Gupta OP, Ho AC, Regillo CD. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol. 2015;159:3\u20138.e1.","journal-title":"Am J Ophthalmol"},{"key":"3370_CR46","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","volume":"125","author":"SD Adrean","year":"2018","unstructured":"Adrean SD, Chaili S, Ramkumar H, Pirouz A, Grant S. Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol. Ophthalmology. 2018;125:1047\u201353.","journal-title":"Ophthalmology"},{"key":"3370_CR47","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00417-020-05016-9","volume":"259","author":"M Figueras-Roca","year":"2021","unstructured":"Figueras-Roca M, Parrado-Carrillo A, Nguyen V, Casaroli-Marano RP, Moll-Udina A, Gillies MC, et al. Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry. Graefes Arch Clin Exp Ophthalmol. 2021;259:1463\u201370.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3370_CR48","first-page":"CD012208","volume":"5","author":"E Li","year":"2020","unstructured":"Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020;5:CD012208.","journal-title":"Cochrane Database Syst Rev"},{"key":"3370_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/IAE.0000000000003283","volume":"42","author":"V Chaudhary","year":"2022","unstructured":"Chaudhary V, Matonti F, Zarranz-Ventura J, Stewart MW. Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: a systematic literature review. Retina. 2022;42:589\u2013606.","journal-title":"Retina"},{"key":"3370_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-016-0207-3","volume":"16","author":"JJ Arnold","year":"2016","unstructured":"Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;16:31.","journal-title":"BMC Ophthalmol"},{"key":"3370_CR51","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: The ARIES study: a randomized clinical trial. Retina. 2021;41:1911\u201320.","journal-title":"Retina"},{"key":"3370_CR52","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"3370_CR53","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ophtha.2016.04.005","volume":"123","author":"U Chakravarthy","year":"2016","unstructured":"Chakravarthy U, Goldenberg D, Young G, Havilio M, Rafaeli O, Benyamini G, et al. Automated identification of lesion activity in neovascular age-related macular degeneration. Ophthalmology. 2016;123:1731\u20136.","journal-title":"Ophthalmology"},{"key":"3370_CR54","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0000000000003385","volume":"42","author":"M Pawloff","year":"2022","unstructured":"Pawloff M, Bogunovic H, Gruber A, Michl M, Riedl S, Schmidt-Erfurth U. Systematic correlation of central subfield thickness with retinal fluid volumes quantified by deep learning in the major exudative macular diseases. Retina. 2022;42:831\u201341.","journal-title":"Retina"},{"key":"3370_CR55","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamaophthalmol.2015.4948","volume":"134","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Philip A-M, Leitner R, Simader C, Langs G, Gerendas BS, et al. Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration. JAMA Ophthalmol. 2016;134:182\u201390.","journal-title":"JAMA Ophthalmol"},{"key":"3370_CR56","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","volume":"125","author":"T Schlegl","year":"2018","unstructured":"Schlegl T, Waldstein SM, Bogunovic H, Endstra\u00dfer F, Sadeghipour A, Philip AM, et al. Fully automated detection and quantification of macular fluid in OCT using deep learning. Ophthalmology. 2018;125:549\u201358.","journal-title":"Ophthalmology"},{"key":"3370_CR57","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bjo-2022-322297","volume":"108","author":"R Martin-Pinardel","year":"2024","unstructured":"Martin-Pinardel R, Izquierdo-Serra J, De Zanet S, Parrado-Carrillo A, Garay-Aramburu G, Puzo M, et al. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database. Br J Ophthalmol. 2024;108:253\u201362.","journal-title":"Br J Ophthalmol"},{"key":"3370_CR58","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajo.2020.12.012","volume":"224","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Chakravarthy U, Loewenstein A, Chew EY, Schmidt-Erfurth U. Automated quantitative assessment of retinal fluid volumes as important biomarkers in neovascular age-related macular degeneration. Am J Ophthalmol. 2021;224:267\u201381.","journal-title":"Am J Ophthalmol"},{"key":"3370_CR59","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40123-021-00381-y","volume":"10","author":"M Stattin","year":"2021","unstructured":"Stattin M, Ahmed D, Graf A, Haas A-M, Kickinger S, Jacob M, et al. The effect of treatment discontinuation during the COVID-19 pandemic on visual acuity in exudative neovascular age-related macular degeneration: 1-year results. Ophthalmol Ther. 2021;10:935\u201345.","journal-title":"Ophthalmol Ther"},{"key":"3370_CR60","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.3390\/jcm10153281","volume":"10","author":"C Arruabarrena","year":"2021","unstructured":"Arruabarrena C, Toro MD, Onen M, Malyugin BE, Rejdak R, Tognetto D, et al. Impact on visual acuity in neovascular age related macular degeneration (nAMD) in Europe due to COVID-19 pandemic lockdown. J Clin Med. 2021;10:3281.","journal-title":"J Clin Med"},{"key":"3370_CR61","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/IAE.0000000000003368","volume":"42","author":"J Zarranz-Ventura","year":"2022","unstructured":"Zarranz-Ventura J, Nguyen V, Creuzot-Garcher C, Verbraak F, O\u2019Toole L, Invernizzi A, et al. International impact of the COVID-19 pandemic lockdown on intravitreal therapy outcomes: Fight Retinal Blindness Registry. Retina. 2022;42:616\u201327.","journal-title":"Retina"},{"key":"3370_CR62","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/IAE.0000000000003369","volume":"42","author":"A Montesel","year":"2022","unstructured":"Montesel A, Gigon A, Giacuzzo C, Mantel I, Eandi CM. Treatment deferral during COVID-19 lockdown: functional and anatomical impact on patients with neovascular age-related macular degeneration. Retina. 2022;42:634\u201342.","journal-title":"Retina"},{"key":"3370_CR63","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/s41433-020-01315-x","volume":"35","author":"KYC Teo","year":"2021","unstructured":"Teo KYC, Nguyen V, Barthelmes D, Arnold JJ, Gillies MC, Cheung CMG. Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence. Eye. 2021;35:2793\u2013801.","journal-title":"Eye"},{"key":"3370_CR64","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41433-020-0960-7","volume":"34","author":"KYC Teo","year":"2020","unstructured":"Teo KYC, Chan RVP, Cheung CMG. Keeping our eyecare providers and patients safe during the COVID-19 pandemic. Eye. 2020;34:1161\u20132.","journal-title":"Eye"},{"key":"3370_CR65","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00417-017-3762-2","volume":"255","author":"P Parvin","year":"2017","unstructured":"Parvin P, Zola M, Dirani A, Ambresin A, Mantel I. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2017;255:2127\u201334.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3370_CR66","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136:786\u201393.","journal-title":"JAMA Ophthalmol"},{"key":"3370_CR67","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/pharmaceutics14020265","volume":"14","author":"D Veritti","year":"2022","unstructured":"Veritti D, Sarao V, Gorni G, Lanzetta P. Anti-VEGF drugs dynamics: relevance for clinical practice. Pharmaceutics. 2022;14:265.","journal-title":"Pharmaceutics"},{"key":"3370_CR68","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"3370_CR69","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141:834\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"3370_CR70","unstructured":"Lanzetta P, Schulze A, Schmidt-Ott U, Zhang X, Berliner A, Chu K, et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. Presented at the European Society of Retina Specialists (EURETINA) Congress, Amsterdam, the Netherlands, 5\u20138 October 2023."},{"key":"3370_CR71","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00417-019-04360-9","volume":"257","author":"AD Abdin","year":"2019","unstructured":"Abdin AD, Suffo S, Asi F, Langenbucher A, Seitz B. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2019;257:1671\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3370_CR72","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/bjophthalmol-2017-310822","volume":"102","author":"CC Wykoff","year":"2018","unstructured":"Wykoff CC, Ou WC, Croft DE, Payne JF, Brown DM, Clark WL, et al. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2018;102:460\u20134.","journal-title":"Br J Ophthalmol"},{"key":"3370_CR73","unstructured":"Singh RP, Stone TW, Hahn P, eds. 2019 Global Trends in Retina Survey. Chicago, IL: American Society of Retina Specialists; 2019."},{"key":"3370_CR74","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/IAE.0b013e31828e8551","volume":"33","author":"N Kumar","year":"2013","unstructured":"Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33:1605\u201312.","journal-title":"Retina"},{"key":"3370_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2013.04.009","volume":"156","author":"AP Schachat","year":"2013","unstructured":"Schachat AP. Switching anti\u2013vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156:1\u20132.E1.","journal-title":"Am J Ophthalmol"},{"key":"3370_CR76","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ophtha.2013.08.035","volume":"121","author":"AA Chang","year":"2014","unstructured":"Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014;121:188\u201392.","journal-title":"Ophthalmology"},{"key":"3370_CR77","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ophtha.2012.08.008","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Chen E, Mariani A, Major JC Jr., Save Study Group. Super-dose Anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration\u2013primary end point. Ophthalmology. 2013;120:349\u201354.","journal-title":"Ophthalmology"},{"key":"3370_CR78","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s10384-018-0619-0","volume":"62","author":"M Mimouni","year":"2018","unstructured":"Mimouni M, Meshi A, Vainer I, Gershoni A, Koren T, Geffen N, et al. Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing. Jpn J Ophthalmol. 2018;62:652\u20138.","journal-title":"Jpn J Ophthalmol"},{"key":"3370_CR79","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2019.10.007","volume":"210","author":"M Gillies","year":"2020","unstructured":"Gillies M, Arnold J, Bhandari S, Essex RW, Young S, Squirrell D, et al. Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions. Am J Ophthalmol. 2020;210:116\u201324.","journal-title":"Am J Ophthalmol"},{"key":"3370_CR80","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1097\/IAE.0000000000002713","volume":"40","author":"DT Wong","year":"2020","unstructured":"Wong DT, Lambrou GN, Loewenstein A, Pearce I, Okada AA, on behalf of the Vision Academy Steering Committee. Suspending treatment of neovascular age-related macular degeneration in cases of futility. Retina. 2020;40:1010\u201320.","journal-title":"Retina"},{"key":"3370_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000499115","volume":"242","author":"VR Juncal","year":"2019","unstructured":"Juncal VR, Francisconi CLM, Altomare F, Chow DR, Giavedoni LR, Muni RH, et al. Same-day bilateral intravitreal anti-vascular endothelial growth factor injections: experience of a large Canadian retina center. Ophthalmologica. 2019;242:1\u20137.","journal-title":"Ophthalmologica"},{"key":"3370_CR82","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/IAE.0000000000002798","volume":"41","author":"EE Cornish","year":"2021","unstructured":"Cornish EE, Teo KY, Nguyen V, Squirrel D, Young S, Gillies MC, et al. Five-year incidence and visual acuity outcomes for intravitreal therapy in bilateral neovascular age-related macular degeneration: Fight Retinal Blindness! project. Retina. 2021;41:118\u201324.","journal-title":"Retina"},{"key":"3370_CR83","doi-asserted-by":"publisher","first-page":"e000985","DOI":"10.1136\/bmjoq-2020-000985","volume":"9","author":"AW Gilbert","year":"2020","unstructured":"Gilbert AW, Billany JCT, Adam R, Martin L, Tobin R, Bagdai S, et al. Rapid implementation of virtual clinics due to COVID-19: report and early evaluation of a quality improvement initiative. BMJ Open Qual. 2020;9:e000985.","journal-title":"BMJ Open Qual"},{"key":"3370_CR84","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/OPTH.S181108","volume":"12","author":"JX Lee","year":"2018","unstructured":"Lee JX, Manjunath V, Talks SJ. Expanding the role of medical retina virtual clinics using multimodal ultra-widefield and optical coherence tomography imaging. Clin Ophthalmol. 2018;12:2337\u201345.","journal-title":"Clin Ophthalmol"},{"key":"3370_CR85","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, Heier JS, Su\u00f1er IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046\u201356.","journal-title":"Ophthalmology"},{"key":"3370_CR86","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying G-S, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"3370_CR87","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1177\/1120672120964699","volume":"31","author":"M Fallico","year":"2021","unstructured":"Fallico M, Lotery AJ, Longo A, Avitabile T, Bonfiglio V, Russo A, et al. Treat and extend versus fixed regimen in neovascular age related macular degeneration: a systematic review and meta-analysis. Eur J Ophthalmol. 2021;31:2496\u2013504.","journal-title":"Eur J Ophthalmol"},{"key":"3370_CR88","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36:1418\u201331.","journal-title":"Retina"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03370-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03370-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03370-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T09:38:37Z","timestamp":1742981917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03370-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3370"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03370-0","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KYCT: Consultancy fees, honorarium, travel support and speaker fees from Bayer, Novartis, Boehringer Ingelheim, Roche, Topcon and Carl Zeiss AG, outside the submitted work. Member of the Eye editorial board. PL: Consultant for Aerie, AbbVie, Apellis, Bausch & Lomb, Bayer, Biogen, Boehringer Ingelheim, Genentech, Novartis, Ocular Therapeutix, Outlook Therapeutics and Roche. BE: Consultant for Allergan, Bayer, Novartis and Roche. AJ: Personal fees from Novartis, Bayer HealthCare Pharmaceuticals, Allergan and Boehringer Ingelheim, as well as grants from Novartis and Bayer HealthCare Pharmaceuticals. AK: AbbVie, Alcon, Apellis, Bayer, Boehringer Mannheim, Carl Zeiss Meditec, Heidelberg, Janssen, Nikon-Optos, Novartis, Roche and Topcon. J-FK: Consultant for Allergan\/AbbVie, Apellis, Bayer, Carl Zeiss Meditec, Janssen, Nano Retina, Roche and Th\u00e9a, and is a member of the Data and Safety Monitoring Boards for Alexion and Novo Nordisk. XL: No financial interests to report. AL: Consultant for Allergan, Annexon, Bayer Healthcare, Beyeonics, Biogen, ForSight Labs, IQVIA, Iveric Bio, Johnson & Johnson, MJH Events, Nano Retina, Notal Vision, Novartis, Ocuphire Pharma, OcuTerra, OphtiMedRx, Roche, Ripple Therapeutics, Syneos, WebMD and Xbrane. ML-A: Consultant for Allergan\/AbbVie, Apellis, Bayer, Novartis, Roche and Santen. RN: Honoraria for consultancy and lecture fees from Bayer HealthCare Pharmaceuticals and Allergan. AAO: Personal fees from AbbVie Japan, Inc., grants and personal fees from Alcon Pharma KK (Japan), personal fees from Astellas Japan, personal fees from Bayer AG, grants and personal fees from Bayer Yakuhin Ltd. (Japan), personal fees from Daiichi-Sankyo, grants and personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Senju Pharmaceutical Co., Ltd., and grants and personal fees from Santen Pharmaceutical Co. Ltd. (Japan). IP: Consultancy, travel and speaker fees from Allergan, Bayer, Novartis and Roche. FR: Consultant for Bayer, Iveric Bio, Johnson & Johnson, Novartis and Roche. DW: Consultant for AbbVie, Alcon, Apellis, Bayer, Bausch Health, Biogen, Boehringer Ingelheim, Novartis, Ripple Therapeutics, Roche, Topcon and Zeiss, has received financial support (to institution) from Bayer, Novartis and Roche, and is an equity owner at ArcticDx. LW: Consultant for Bayer, Lumibird Medical, Novartis and Roche. DZ: Received grants from Roche, has served on scientific advisory boards for AbbVie, Allergan, Bayer, Johnson & Johnson, Novartis and Roche, and has been a speaker for AbbVie, Allergan, Bayer, Novartis and Roche. JZ-V: Received grants from AbbVie, Allergan, Bayer, Novartis and Roche, has served on scientific advisory boards for AbbVie, Allergan, Bayer, Novartis and Roche, and has been a speaker for AbbVie, Alcon, Alimera Sciences, Allergan, Bausch & Lomb, Bayer, Brill Pharma, DORC, Esteve, Novartis, Roche, Topcon Healthcare and Zeiss. Member of the Eye editorial board. PM: Received consulting fees from Allergan, Apellis, Bayer, Novartis, and Roche, lecture honoraria from Bayer, support for attending meetings and\/or travel from Bayer and Roche, and he is a member of data safety monitoring boards or advisory boards for Apellis and Bayer. VC: Advisory board member for Alcon, Roche, Bayer, Novartis, Apellis and Boehringer Ingelheim, and received grants from Bayer, Novartis and Roche. Member of the Eye editorial board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}